Koga Masatoshi
Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
J Neuroendovasc Ther. 2025;19(1). doi: 10.5797/jnet.ra.2024-0001. Epub 2024 Mar 13.
Antithrombotic therapy plays a crucial role in secondary prevention following ischemic stroke from the acute phase. Numerous trials, along with a meta-analysis, contributed to establishing aspirin as the primary medication for secondary stroke prevention. According to the Cochrane Database of Systematic Review 2022, initiating antiplatelet therapy with aspirin at a dose of 160 mg to 300 mg daily within 48 hours of stroke onset reduces the risk of death or dependency at the end of follow-up. Other antiplatelet drugs, such as clopidogrel, cilostazol, prasugrel, and intravenous ozagrel sodium, are also available within the Japanese Health Care Insurance System. Two pivotal trials from the 2010s underscored the effectiveness and safety of dual antiplatelet therapy (DAPT) using aspirin and clopidogrel, administered for 21 days to 3 months following acute ischemic stroke or transient ischemic attack. However, the extension of DAPT with aspirin and clopidogrel beyond 3 months may result in substantial bleeding risks. Although prasugrel offers a rapid, potent, and consistent inhibition of platelet aggregation and can be used in place of clopidogrel, there is a lack of substantial real-world clinical data on its use in acute ischemic stroke. It is important to recognize that antiplatelet drugs might not be beneficial and could even increase the risk of hemorrhagic events in cardioembolic stroke. In cases of ischemic stroke with nonvalvular atrial fibrillation, direct oral anticoagulants are the primary choice if applicable. Warfarin continues to be the anticoagulant of choice for secondary stroke prevention in patients with mechanical valve replacements. In patients who have undergone intravenous thrombolysis, antithrombotic therapy is generally delayed for up to 24 hours, although there are no definitive guidelines for the period during and immediately after mechanical thrombectomy. This review provides an overview of the current status of antithrombotic therapy for acute ischemic stroke.
抗栓治疗在急性缺血性卒中后的二级预防中起着关键作用。众多试验以及一项荟萃分析促使阿司匹林成为二级卒中预防的主要药物。根据《Cochrane系统评价数据库2022》,在卒中发作后48小时内开始每日服用160毫克至300毫克剂量的阿司匹林进行抗血小板治疗,可降低随访结束时死亡或依赖的风险。日本医疗保险体系中也有其他抗血小板药物,如氯吡格雷、西洛他唑、普拉格雷和静脉注射奥扎格雷钠。21世纪10年代的两项关键试验强调了在急性缺血性卒中或短暂性脑缺血发作后使用阿司匹林和氯吡格雷进行21天至3个月的双联抗血小板治疗(DAPT)的有效性和安全性。然而,阿司匹林和氯吡格雷的DAPT超过3个月可能会带来大量出血风险。尽管普拉格雷能快速、强效且持续地抑制血小板聚集,可用于替代氯吡格雷,但缺乏关于其在急性缺血性卒中应用的大量真实世界临床数据。必须认识到,抗血小板药物可能并无益处,甚至可能增加心源性栓塞性卒中出血事件的风险。对于非瓣膜性心房颤动所致的缺血性卒中,若适用,直接口服抗凝剂是首选。华法林仍是机械瓣膜置换患者二级卒中预防的首选抗凝剂。在接受静脉溶栓治疗的患者中,抗栓治疗通常会延迟长达24小时,不过对于机械取栓期间及之后的这段时间,尚无明确的指南。本综述概述了急性缺血性卒中抗栓治疗的现状。